Pharmacology and Therapeutics

  1. Features of Inflammatory Heart Reactions Following mRNA COVID‐19 Vaccination at a Global Level

    1. Laurent Chouchana
    2. Alice Blet
    3. Mohammad Al‐Khalaf
    4. Tahir S. Kafil
    5. Girish Nair
    6. James Robblee
    7. Milou‐Daniel Drici
    8. Marie‐Blanche Valnet‐Rabier
    9. Joëlle Micallef
    10. Francesco Salvo
    11. Jean‐Marc Treluyer
    12. Peter P. Liu

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  2. Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV)

    1. Eugene Sobngwi
    2. Sylvain Zemsi
    3. Magellan Guewo-Fokeng
    4. Jean-Claude Katte
    5. Charles Kounfack
    6. Liliane Mfeukeu-Kuate
    7. Armel Zemsi
    8. Yves Wasnyo
    9. Antoinette Assiga Ntsama
    10. Arnaud Ndi-Manga
    11. Joelle Sobngwi-Tambekou
    12. William Ngatchou
    13. Charlotte Moussi Omgba
    14. Jean Claude Mbanya
    15. Pierre Ongolo Zogo
    16. Pierre Joseph Fouda

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  3. Vaccines against Covid-19, venous thromboembolism, and thrombocytopenia. A population-based retrospective cohort study

    1. Joan-Ramon Laporte
    2. Ermengol Coma
    3. Francesc Fina
    4. Luís García-Eroles
    5. Xavier Vidal
    6. Manuel Medina

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  4. Virlaza™ Inhibits Sars-COV-2-induced Inflammatory Response of Bronchial Epithelial Cells and Pulmonary Fibroblast

    1. Maysa Alves Rodrigues Brandao-Rangel
    2. Dobroslav Melamed
    3. Anamei Silva-Reis
    4. Boris Brill
    5. Lucas dos Santos Zamarioli
    6. Carlos Rocha Oliveira
    7. Rodolfo P Vieira

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  5. SGLT2‐Inhibition reverts urinary peptide changes associated with severe COVID‐19: An in‐silico proof‐of‐principle of proteomics‐based drug repurposing

    1. Agnieszka Latosinska
    2. Justyna Siwy
    3. David Z. Cherney
    4. Bruce A. Perkins
    5. Harald Mischak
    6. Joachim Beige

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  6. Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol

    1. Arvind Chopra
    2. Preeti Chavan-Gautam
    3. Girish Tillu
    4. Manjit Saluja
    5. Swapnil Borse
    6. Sanjeev Sarmukaddam
    7. Susmita Chaudhuri
    8. BCS Rao
    9. Babita Yadav
    10. Narayanam Srikanth
    11. Bhushan Patwardhan

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  7. Safety and Pharmacokinetics of Intranasally Administered Heparin

    1. Hannah M. Harris
    2. Katherine L. Boyet
    3. Hao Liu
    4. Rohini Dwivedi
    5. Nicole M. Ashpole
    6. Ritesh Tandon
    7. Gene L. Bidwell
    8. Zhi Cheng
    9. Lauren A. Fassero
    10. Christian S. Yu
    11. Vitor H. Pomin
    12. Dipanwita Mitra
    13. Kerri A. Harrison
    14. Eric Dahl
    15. Bill J. Gurley
    16. Arun Kumar Kotha
    17. Mahavir Bhupal Chougule
    18. Joshua S. Sharp

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  8. Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?

    1. Jessica M. Conway
    2. Pia Abel zur Wiesch

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  9. BNT162b2 COVID-19 VACCINATION AND ITS EFFECT ON BLOOD PRESSURE

    1. Toh Leong Tan
    2. Sharifah Azura Salleh
    3. Zuraidah Che Man
    4. Michelle Hwee Peng Tan
    5. Rashid Kader
    6. Razman Jarmin

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  10. Coadministration of AYUSH 64 as an adjunct to Standard of Care in mild and moderate COVID-19: A randomised, controlled, multicentric clinical trial

    1. Arvind Chopra
    2. Girish Tillu
    3. Kuldeep Chuadhary
    4. Govind Reddy
    5. Alok Srivastava
    6. Muffazal Lakdawala
    7. Dilip Gode
    8. Himanshu Reddy
    9. Sanjay Tamboli
    10. Manjit Saluja
    11. Sanjeev Sarmukkaddam
    12. Manohar Gundeti
    13. Ashwinikumar Raut
    14. BCS Rao
    15. Babita Yadav
    16. Narayanam Srikanth
    17. Bhushan Patwardhan

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity
Previous Page 5 of 8 Next